Term
|
Definition
| treatment for RCC, induces cell death, requires ICU admission due to 103F fever/HTN/causes immunocompromise |
|
|
Term
|
Definition
| tyrosine kinase inhibitor against VEGFR-1&2&3/PDGFR/cKit/Flt-3 |
|
|
Term
|
Definition
| tyrosine kinase inhibitor against VEGFR2&3/PDGFR-B/FLT3/Raf-1 |
|
|
Term
|
Definition
|
|
Term
|
Definition
| tyrosine kinase inhibitor against VEGFR2, EGFR, and RET |
|
|
Term
|
Definition
| tyrosine kinase inhibitor against VEGR-1&2&3/PDGFR/cKit |
|
|
Term
|
Definition
| VEGF aptamer, for wet AMD |
|
|
Term
|
Definition
| Fab from humanized VEGF mAb, for wet AMD |
|
|
Term
|
Definition
| VEGF-A blocking antibody, for colorectal cancer/NSCLC/glioblastoma multiforme |
|
|
Term
|
Definition
| IgG1 Fc with VEGFR1 subunit 2 and VEGFR2 subunit 3 |
|
|
Term
|
Definition
|
|
Term
|
Definition
| estrogen receptor antagonist, converted to endoxifen by CYP2D6 |
|
|
Term
|
Definition
| antibody against HER2, complement-mediated toxicity, blockade of signal transduction, cardiotoxicity |
|
|
Term
| imatinib mesylate (gleevac) |
|
Definition
| tyrosine kinase inhibitor for BCR-abl/c-kit/PDGFR, T315I mutation causes resistance, neutorpenia/thrombocytopenia, hepatic/renal toxicity, not during pregnancy |
|
|
Term
|
Definition
| antibody against IL-5, treats hypereosinophilic syndrome |
|
|
Term
|
Definition
|
|
Term
|
Definition
| reduces Fe3+ to Fe2+, treatment for methemoglobinemia |
|
|
Term
|
Definition
| CADET- CO2/Acid/DPG/Exercise/Temperature |
|
|
Term
| Anthracycline, vincas, taxanes, epidophyllotxins |
|
Definition
| drugs susceptible to increased efflux |
|
|
Term
|
Definition
| vaccine against HPV 6,11,16,18 |
|
|
Term
|
Definition
| APCs taken from patient are treated with prostate-cancer associated antigen (PAP), matured with GM-CSF, returned to patient to activate Tcells, for HRPC |
|
|
Term
| Mechloremethane (Nitrogen Mustard) |
|
Definition
| bifunction alkylating agent, 1st antineoplastic drug, risk of extravasation injuries |
|
|
Term
| Cyclophosphamide (nitrogen mustard) |
|
Definition
| alkylating agent, bioactivated by liver p450 to 4-OH-cyclophosphamide, acrolein metabolite causes renal/bladder toxicity, interacts with P450 drugs |
|
|
Term
|
Definition
| covalent binding to DNA/RNA/proteins, cell-cycle nonspecific, dose-limiting based on bone marrow suppression, mutagenic/carcinogenic, resistance via DNA repair/detoxification/apoptosis |
|
|
Term
|
Definition
| cyclphosphamide metabolite, responsible for bladder/renal toxicity |
|
|
Term
|
Definition
| neutralizes acrolein, prophylactic with cyclophosphamide |
|
|
Term
|
Definition
| alkylating agent, spontaneous activity, lipid soluble, crosses BBB |
|
|
Term
|
Definition
| difunctional alkylating agent, oral absorption and rapid degradation, cumulative myelosuppression, for brain tumors |
|
|
Term
|
Definition
| monofunctional alkylating agent, uptaken by GLUT2, accumulates in liver/kidneys/pancreas, diabetogenic (destruction of B-cells), renal/liver toxicity, for pancreatic cancers |
|
|
Term
|
Definition
| cross-links DNA, resistance via detox/DNA repair/uptake/efflux/apoptosis, pronounced hypersensitivity/vomting, dose-limiting renal toxicity, peripheral and central neurotoxicity, hearing loss from acoustic nerve damage |
|
|
Term
|
Definition
| DNA intercalation/ssDNA breaks/topoisomerase II inhibition, cell cycle non-specific, resistance via efflux/Topoisomerase II affinity and expression/DNA repair/GST detox |
|
|
Term
|
Definition
| intercalates DNA/inhibits topoisomerase II, dose-limiting myelosuppression, risk of extravasation injury, increased sensitivity to UV radiation |
|
|
Term
|
Definition
| IV, bioactivated in liver, cross-links DNA/generates ROS for DNA damage, cumulative myelosuppression, kidney damage & lung fibrosis |
|
|
Term
|
Definition
| intercalates DNA/forms ROS for DNA damage, metabolized by bleomycin hydrolase, dose-limiting pulmonary fibrosis, hypersensitivity/skin hyperpigmentation/lung toxicity |
|
|
Term
|
Definition
| topoisomerase II/helicase inhibitors, DNA intercalation, ROS formation |
|
|
Term
|
Definition
| anthracyclines, dose-limiting myelosuppression, cardiac toxicity/EKG changes, <400mg/m2 cumulative lifetime dose, RECORD ALL DOSING, risk of extravasation injury |
|
|
Term
|
Definition
| interfere with DNA/RNA synthesis and protein synthesis, S-phase selective, actively transported into cells |
|
|
Term
|
Definition
| inhibits dihydrofolate reductase, prevents tetrahydrofolate formation, dose-limiting myelosuppression, renal toxicity at high doses, liver toxicity at chronic use, rescued with folinic acid |
|
|
Term
|
Definition
| false nucleotides (5-UTP) incorporated into DNA/RNA pyrimidines, inhibits thymidylate synthase, enhanced by folinic acid, fatal reaction with dihydropyrimidine dehydrogenase deficiency |
|
|
Term
|
Definition
|
|
Term
|
Definition
| circumvents folic acid pathway, rescues normal cells after methotrexate, enhances 5-FU activity |
|
|
Term
|
Definition
| purine analogue converted by HGPRTase, triphosphate form incorporated into DNA for damage, monophosphate form inhibits purine synthesis, TPMT catalyzes 5-methylation (deficiency causes adverse effects), reduced clearance with allopurinol |
|
|
Term
|
Definition
| inhibits xanthine oxidase, reduces 6-mercaptopurine clearance |
|
|
Term
|
Definition
| resistance via efflux/protein mutation |
|
|
Term
|
Definition
| depolymerization of microtubules, block cells in G2/M phases, resistance via tubulin synthesis/efflux, fatal if given intrathecal, risk of extravasation injury |
|
|
Term
|
Definition
| increased neurotoxicity, decreased myelosupression, neurotoxicity-limiting |
|
|
Term
|
Definition
| increased myelosuppression, decreased neurotoxicity, myelosuppression-limiting |
|
|
Term
|
Definition
| stabilize microtubules, block G2-M transition, peripheral neuropathy |
|
|
Term
| dexamethason, prednisone, prednisolone (gluocorticoids) |
|
Definition
| induce apoptosis in lymphocytes, anti-inflammatory to prevent immune cell proliferation, orally available, supportive during during chemo to protect against anthracycline cardiac toxicity, adrenal atrophy, impaired wound healing, systemic infections, HTN/fluid & Na+ retention/edema/CHF, don't use in Cushing's Syndrome/CHF/HTN/diabetes/osteoporosis |
|
|
Term
|
Definition
| activated in liver to SN-38, inhibits topoisomerase I/ssDNA unwinding/DNA breaks, inactivated by glucuronide, decreased metabolism in Glibert's Disease |
|
|
Term
| etoposide, teniposide (epipodophyllotoxins) |
|
Definition
| inhibit topoisomerase II, S/G2 phase specific, resistance via efflux, myelosuppression |
|
|
Term
|
Definition
| EGFR antibodies, IgG1 humanized (cetuximab), IgG2 fully human (panitumumab), binds HER1, for patients with non-mutated Kras, interstitial lung disease, skin rash worsened by sun exposure, avoid use in pregnancy |
|
|
Term
|
Definition
| binds CD20 on Bcells, complement-mediated toxicity, moderate allergic reactions, rare cases of fatal reactions |
|
|
Term
|
Definition
| binds CD20 on Bcells, IgG1 with radioisotope, first dose has indium-111 for imaging, second dose has yttrium-90 for B-radiation |
|
|
Term
|
Definition
| tyrosine kinase inhibitor of EGFR, weakness and risk of fatal bleeding |
|
|
Term
|
Definition
| inhibits 26S proteasome, decreases protein degradation, disruption of cell signaling/cell cycle arrest/ apoptosis/decreased angiogenesis, decreased tumor growth/increased cytotoxic effects of radiation |
|
|
Term
| thalidomide, lenalidomide |
|
Definition
| direct anti-tumor activity, inhibits TNFa/IFN/IL, inhibition of VEGF/bFGF, black box warning for blood clotting, birth defects due to loss of immature blood vessels during development |
|
|
Term
| methotrexate, hydroxyurea, AZT, phenytoin |
|
Definition
| affect DNA sequence and cause megaloblastic anemia |
|
|
Term
|
Definition
|
|
Term
| Folic acid, tansfusions, hydroxyurea, BMT |
|
Definition
| treatment for sickle cell disease |
|
|
Term
| Antimalarials, sulfonamides, nitrofurantoin, phenaceptin, aspirin, vitamin K |
|
Definition
| drugs that generate ROS, exacerbate G6PD |
|
|
Term
|
Definition
| binds BFU-E/CFU-E to simulate maturation, for chronic renal failure/anemia of aids/surgery/autologous donation, reduces need for transfusions, limited value to 1-2 units, IV/SC, target Hct 33-36%, resistance due to inflammation or nutrient deficiency, causes HTN in renal failure (reversible with anti-HTN and decreased drug) |
|
|
Term
|
Definition
| 2 more carbohydrate chains than rHuEPO, increased half-life |
|
|
Term
|
Definition
| G-CSF, increases neutrophils, for autologous BMT/congenital neutropenia, mild-moderate bone pain, granulocytosis, mild-moderate splenomegaly |
|
|
Term
|
Definition
| G-CSF, pegylated form of filgastrim, longer half-life |
|
|
Term
|
Definition
| GM-CSF, for autologous BMT/neutropenia of AIDS or chemo/stimulating myelopoiesis, more severe side-effects than G-CSF (generally not used) |
|
|
Term
|
Definition
| rhIL-11, stimulates megakaryocytopoiesis, for high-dose cancer patients |
|
|
Term
|
Definition
| stimulates thrombopoietin receptor Mpl, coupled to 2 Fc fragments, increased half life, for idiopathic thrombocytopenia purpura |
|
|
Term
|
Definition
| Fe2+ absorbed more readily, absorbed in upper small intestine, take before meals, antacids reduce bioavailability, spread doses throughout day to not interrupt RBC production, absorption is non-linear, 200mg/day adults, 120mgx4/day deficients, increased 15-30mg/day in prevention therapy |
|
|
Term
| Parenteral iron (sodium ferric gluconate, iron sorbitol, iron sucrose) |
|
Definition
| anaphylactic reaction to iron dextran, for oral iron intolerance/malabsorption/supplemented TPN/conjoined EPO therapy |
|
|
Term
| Vitamin B12 (cyanocobalamin, hydroxocobalamin) |
|
Definition
| converts N5-methyltetrahydrofolate to tetrahydrofolate, deficiency depletes folate pools, neurological sequelae, due to insufficient digestive enzymes/insufficient IF/deficiency of transcobalamin II, IM or deep SC, oral if not deficits in absorption |
|
|
Term
|
Definition
| RDV non-pregnant people is 400ug, >600ug/day if pregnant or bleeding, prevents neural tube defects, destoryed by cooking, hepatic modification and recirculation into gut, oral or parenteral if absorption is defective, relives megaloblastic anemia, does not relive mental deficits due to B12 deficiency |
|
|
Term
|
Definition
| 5-formyl modification, circumvents DHFR, for congenital DHFR deficiency |
|
|
Term
| ondansetron & granisetron |
|
Definition
| serotonin receptor agonists, for nausea/vomiting |
|
|
Term
|
Definition
| DA receptor agonist, for nausea/vomiting |
|
|
